Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
290.78+0.13 (+0.04%)
At close: 4:00 PM EDT

290.78 0.00 (0.00%)
After hours: 4:41 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close290.65
Bid290.78 x 900
Ask293.20 x 500
Day's Range290.00 - 293.40
52wk Range223.02 - 333.65
1y Target EstN/A
Market Cap63.72B
P/E Ratio (ttm)16.99
Avg Vol (3m)1,568,714
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC
    Investor's Business Daily43 minutes ago

    Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC

    Biogen could add another $1 billion in 2017 sales if its myotonic dystrophy drug garners strong trials data by year's end, says an analyst.

  • American City Business Journals54 minutes ago

    Here's the big news we're likely to hear when Vertex, Biogen report Q3 this week

    Earnings season for our Massachusetts biotech giants kicks off this week when Vertex Pharmaceuticals reports its third quarter financials on Tuesday evening, followed by Biogen on Wednesday morning. While probably just a fluke, it’s unusual for Vertex (VRTX) to be the first local biotech to give a quarterly update, as that honor usually goes to Biogen (BIIB). Vertex : To some extent, the financial news expected from the Boston-based company is already old news.

  • TheStreet.com2 hours ago

    What to Look for When Biogen (BIIB) Reports Q3 Results

    On Wednesday Biogen (BIIB) is projected to post third-quarter earnings and revenue that have improved from a year ago.